π UPDATE β May 22, 2026
Neuralink has released new video footage showing Audrey β the same clinical trial participant featured in this article β using her brain-computer interface to play video games entirely with her mind. The demonstration expands on her previously highlighted artistic abilities, underscoring the broader range of tasks BCI can now enable for paralyzed users. Neuralink accompanied the release with a disclaimer noting that its devices remain investigational and are not yet FDA approved, and that individual experiences may vary across trial participants.
Twenty years after a car accident left her paralyzed from the neck down, Audrey Crews is drawing again β not with her hands, but with her thoughts. Neuralink shared her story on May 15, revealing that Crews, the ninth human and first woman to receive their brain-computer interface implant, is now using the device to create art entirely through neural signals.
Crews β identified as participant P9 in Neuralink's PRIME clinical trial β sustained a C4/C5 spinal cord injury in a 2005 accident that resulted in quadriplegia. The implant she received, called Telepathy, sits roughly the size of a quarter (23 mm across, about 8 mm thick) and is placed in the motor cortex via a small opening in the skull. From there, 128 ultra-thin threads carrying over 1,000 electrodes pick up neural signals and transmit them wirelessly via Bluetooth to a computer running Neuralink's custom software. The result: Crews can move a cursor, write her name, and now produce drawings β all by thinking.
Neuralink was careful to attach a standard disclaimer to the announcement: the devices remain investigational and are not FDA-approved for general use. The FDA initially rejected Neuralink's application for human trials in 2022 over safety concerns, then granted an investigational device exemption in May 2023. As of early 2026, 21 participants were enrolled globally in the PRIME study, with no serious device-related adverse events reported to date.
The broader timeline is worth keeping in mind. Neuralink is targeting a high-volume implant rollout in 2026, contingent on anticipated FDA clearance, and has a $650 million funding boost backing that push. The company also aims to transition to an almost entirely automated surgical procedure this year. Commercial availability for limited patient populations is projected between 2028 and 2030. Audrey Crews creating art with her mind today is, in that context, both a deeply personal milestone and a proof-of-concept for a technology that is moving faster than most people realize.
Sources & reporting notes
The links below identify the material source records used for this report.
- @neuralink on X (2026-05-15T18:15:22.000Z) β Direct source
- @neuralink on X (2026-05-15T18:15:23.000Z) β Direct source
- @neuralink on X (2026-05-22T21:54:25.000Z) β Direct source
- @neuralink on X (2026-05-22T21:54:25.000Z) β Direct source
Source links are preserved as published or accessed. See our editorial standards and corrections policy.
The BASENOR Editorial Desk covers Tesla, SpaceX, and related technology, curating reporting from primary sources β official accounts, regulatory filings, and software release data. Every article passes source-record and fact-checking review before publication. About the newsroom.
This report was curated by the BASENOR Editorial Desk from the sources listed above. Read our editorial standards or email editorial@basenor.com to report an error.
